Skip to content

Amneal Pharmaceuticals

US · AMRX #1854 by market cap Listed 1970
21.12 -0.27 -1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 21.40 +0.05%
After-hours 21.78 +3.15%
Overnight 21.35 -0.19%
21.8812.6521.122026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AMRX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +50.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall C
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 52.8x Better than 9%
Forward P/E 38.1x Better than 11%
Price / Sales 2.3x Better than 52%
P/E vs own 5-yr range 69th pctl Better than 39%
Growth C+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 10.9% Better than 67%
Net income CAGR (3Y) -18.4% Better than 19%
Free cash flow CAGR (3Y) 5.2% Better than 46%
Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 36.9% Better than 43%
Operating margin 13.2% Better than 60%
Net margin 2.4% Better than 34%
Return on equity -52.8% Better than 9%
Return on invested capital 2.4% Better than 35%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 17.9% Better than 95%
6-month return 70.0% Better than 98%
12-month return (ex latest month) 70.5% Better than 90%
Distance below 52-week high 4.5% Better than 95%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.2x Better than 60%
Debt to assets 73.1% Better than 5%
Interest coverage 1.6x Better than 33%
Free cash flow / net income 313.1% Better than 86%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 15.5% Better than 24%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.22%
1M +6.45%
3M +17.99%
6M +72.69%
YTD +67.62%
1Y +83.41%
3Y +370.38%
5Y +357.14%

Key statistics

Price & volume

Prev close
21.39
Open
21.26
Day range
21.07 - 21.71
Avg price
21.22
Volume
1.67M
Turnover
35.50M
Amplitude
2.99%
52-week range
11.71 - 22.13

Valuation

P/E
96.00
P/E (TTM)
52.80
P/B
13.85
EPS
0.22
Net profit
76.65M
Net assets
531.33M

Share structure

Market cap
7.36B
Float cap
4.03B
Shares out
348.41M
Float shares
190.89M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 90% of range
11.71 22.13

4.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-5.52M net over the window

Short interest

Shares short
11.39M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Amneal Pharmaceuticals (AMRX)?

Amneal Pharmaceuticals last traded at 21.12. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Amneal Pharmaceuticals's market cap?

About 7.36B.

What is the P/E ratio of Amneal Pharmaceuticals?

The trailing twelve-month P/E is 52.80, below its own 5-year average of 122.82 — toward the top of its historical range (68.82% percentile). See the Valuation tab for the full history.

Does Amneal Pharmaceuticals pay a dividend?

Amneal Pharmaceuticals does not currently pay a regular dividend.

Is Amneal Pharmaceuticals a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 24.40, which implies 15.5% upside from the current price. This is not investment advice.

What is Amneal Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Amneal Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.

Amneal Pharmaceuticals discussion 0 comments

Add a comment